Hepatic steatosis in HIV/HCV-coinfected patients: Time to reevaluate!

Gastroenterology

Volumn 140, Issue 3, 2011, Pages 772-775

  McGovern, Barbara H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EMTRICITABINE; INDINAVIR; LOPINAVIR; NELFINAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ALCOHOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATTY LIVER; HEPATITIS C; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPOLYSIS; LIVER CIRRHOSIS; LIVER FIBROSIS; MITOCHONDRIAL TOXICITY; MIXED INFECTION; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 79952306665     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.01.025     Document Type: Editorial

References (33)

1. L.A. Adinolfi, M. Gambardella, and A. Andreana Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity Hepatology 33 2001 1358 1364 (Pubitemid 32496971)
2. L. Fartoux, A. Poujol-Robert, and J. Guechot Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C Gut 54 2005 1003 1008 (Pubitemid 40873917)
3. I. Gaslightwala, and E.J. Bini Impact of HIV infection on the prevalence and severity of steatosis in patients with chronic HCV J Hepatol 44 2006 1026 1032
4. L. Castera, M.A. Loko, and B. LeBail Hepatic steatosis in HIV-infected patients in France: comparison with HCV-monoinfected patients matched for BMI and genotype Aliment Pharmacol Ther 26 2007 1489 1498 (Pubitemid 350178805)
5. M.A. Noor, O.P. Flint, and J.F. Maa Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity AIDS 20 2006 1813 1821
6. M. Dube, C. Shen, and M. Greenwald No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection Clin Infect Dis 47 2008 567 574
7. R. Blumer, M. van Vonderen, and J. Sutinen Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy AIDS 22 2008 227 236
8. P.C. Tien, M.F. Schneider, and S.R. Cole Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV Study J Acquir Immune Defic 49 2008 369 376
9. B. McGovern, J.S. Ditelberg, and L.E. Taylor Hepatic steatosis is associated with fibrosis, nucleoside analog use and hepatitis C virus genotype 3 infection in HIV seropositive patients Clin Infect Dis 43 2006 365 372 (Pubitemid 44078910)
10. W.M. El-Sadr, J.D. Lundgren, and J.D. Neaton CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296 (Pubitemid 44837777)
11. L.H. Kuller, R. Tracy, and W. Belloso Inflammatory and coagulation biomarkers and mortality in patients with HIV infection PLoS Med 5 2008 e203
12. T.A. Woreta, C.G. Sutcliffe, and S.H. Mehta Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus Gastroenterology 140 2011 809 817
13. R. Sterling, M.J. Contos, and P.G. Smith Steatohepatitis: Risk factors and disease impact on HIV/HCV coinfection Hepatology 47 2008 1118 1127
14. T. Brown, S.H. Mehta, and C. Sutcliffe Hepatic steatosis is associated with increased central body at by dual-energy X-ray absorptiometry and uncontrolled HIV in coinfected persons AIDS 24 2010 811 817
15. N. Brau, M. Salvatore, and C. Rios-Bedoya Slower fibrosis progression in HIV/HCV co-infected patients with successful viral suppression using antiretroviral therapy J Hepatol 44 2006 47 55 (Pubitemid 41772515)
16. K.E. Sherman, J.W. Andersen, and A.A. Butt Sustained long-term antiviral maintenance therapy in HIV/HCV coinfected patients J Acquir Immune Defic Syndr 55 2010 597 605
17. J.M. Brenchley, D.A. Price, and T.W. Schacker Microbial translocation is a cause of systemic immune activation in chronic HIV infection Nat Med 12 2006 1365 1371 (Pubitemid 44924494)
18. A. Balagopal, F. Philp, and J. Astemborski Human immunodeficiency virus and microbial translocation and progression of hepatitis C Gastroenterology 135 2008 226 233 (Pubitemid 351899010)
19. Prospective Studies Collaboration BMI and cause-specific mortality in 900,000 adults Lancet 373 2009 1083 1096
20. Y. Shitani, H. Fujie, and H. Miyoshi Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 146 2004 840 848 (Pubitemid 38298332)
21. R. Moucari, T. Asselah, and D. Cazals-Hatem Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level and fibrosis Gastroenterology 135 2008 416 423 (Pubitemid 351181308)
22. J. Hui, A. Sud, and G.C. Farrell Insulin resistance is associated with chronic hepatitis C and fibrosis progression Gastroenterology 125 2003 1695-1674
23. W. Lin, E.M. Weinberg, and A.W. Tai HIV increases HCV replication in a TGF-beta1-dependent manner Gastroenterology 134 2008 803 811 (Pubitemid 351312737)
24. R. Scherzer, W. Shen, and P. Bacchetti Simple anthropometric measures correlate with metabolic risk indicators as strongly as MRI measures Am J Clin Nutr 87 2008 1809 1817
25. J. Berenguer, J. Alvarez-Pellicer, and P.M. Martin Sustained virologic response to interferon and ribavirin reduces liver-related complications and mortality in patients coinfected with HIV/HCV Hepatology 50 2009 407 413
26. L. Backus, D. Boothroyd, and B.R. Phillips Impact of sustained virologic response to pegylated interferon and ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: the US Department of Veterans Affairs Experience Hepatology 52 2010 51A
27. H. Conjeevaram, A.S. Wadhed, and N. Afdhal Changes in insulin sensitivity and body weight during and after pegylated interferon and ribavirin therapy for hepatitis C Gastroenterology 2010 Nov 9 [Epub ahead of print]
28. M. Rodriguez-Torres, S. Govindararajan, and R. Sola Hepatic steatosis in HIV/HCV coinfected patients Correlates, efficacy, and outcomes of anti-HCV therapy J Hepatol 48 2008 756 764
29. F. van Leth, P. Phanuphak, and E. Stroes Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-nave HIV-infected patients PLoS Med 2004 e19
30. M.J. Silverberg, W. Leyden, and L. Hurley Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection Ann Intern Med 150 2009 301 313
31. P. Bacchetti, B. Gripshover, and C. Grunfeld Fat distribution in men with HIV infection J Acquir Immune Defic Syndr 40 2005 121 131 (Pubitemid 41395709)
32. A.M. Kesselring, F.W. Wit, and C.A. Sabin Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy AIDS 23 2009 1689 1699
33. J. Falutz, J. Mamputu, and D. Potvin Effects of tesamorelin, a growth-hormone releasing analog in HIV-infected patients with excess abdominal fat J Clin Endocrinol Metab 95 2010 4291 4304